Allogeneic stem cell transplantation for renal cell carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Transplantation

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is an established adoptive immunotherapy for metastatic, cytokine-refractory renal cell carcinoma (RCC).
• Since 2000, studies show a graft-versus-tumor effect in RCC patients post-reduced-intensity HSCT, with response rates of 20-40%.
• However, HSCT for RCC is associated with high transplant-related mortality (10-20%) and limited durability of responses.

Purpose of the Study:

• To review the efficacy and limitations of allogeneic HSCT in renal cell carcinoma.
• To explore the immunological mechanisms underlying the graft-versus-RCC effect.
• To discuss the potential of novel targeted agents in combination with HSCT or adoptive cell therapy.

Main Methods:

• Review of experimental evidence and clinical investigations on allogeneic HSCT for RCC.
• Identification of key cellular mediators (T cells, NK cells) and target antigens of the graft-versus-RCC effect.
• Analysis of the impact of molecularly targeted agents on HSCT utilization in RCC.

Main Results:

• Donor-derived T cells and natural killer cells mediate the graft-versus-RCC effect.
• Specific target antigens (minor histocompatibility antigens, HERV-E, WT1) have been identified, enabling antigen-specific adoptive cell therapy.
• The advent of targeted therapies (e.g., sunitinib, sorafenib, bevacizumab) has reduced the use of allogeneic HSCT.

Conclusions:

• Allogeneic HSCT can induce responses in RCC but is limited by significant mortality and lack of durable remission.
• Understanding graft-versus-RCC mechanisms and identifying specific antigens pave the way for targeted adoptive cell therapies.
• Combination strategies involving targeted agents with HSCT or adoptive cell therapy may improve cure rates for RCC.